195 related articles for article (PubMed ID: 18417998)
1. Screening advances and diagnostic choice: the problem of residual risk.
Henry GP; Britt DW; Evans MI
Fetal Diagn Ther; 2008; 23(4):308-15. PubMed ID: 18417998
[TBL] [Abstract][Full Text] [Related]
2. The evolving national birth prevalence of Down syndrome in Taiwan. A study on the impact of second-trimester maternal serum screening.
Jou HJ; Kuo YS; Hsu JJ; Shyu MK; Hsieh TT; Hsieh FJ
Prenat Diagn; 2005 Aug; 25(8):665-70. PubMed ID: 16049991
[TBL] [Abstract][Full Text] [Related]
3. [Prenatal diagnosis of Down syndrome in Denmark 1980-1998 and future progress perspectives].
Larsen SO; Hansen J; Christiansen M; Nørgaard-Pedersen B
Ugeskr Laeger; 2002 Sep; 164(39):4532-6. PubMed ID: 12380396
[TBL] [Abstract][Full Text] [Related]
4. The impact of first-trimester screening on AMA patients' uptake of invasive testing.
Wray AM; Ghidini A; Alvis C; Hodor J; Landy HJ; Poggi SH
Prenat Diagn; 2005 May; 25(5):350-3. PubMed ID: 15906421
[TBL] [Abstract][Full Text] [Related]
5. Fetal Down syndrome screening: a cost effectiveness analysis of alternative screening programs.
Cusick W; Vintzileos AM
J Matern Fetal Med; 1999; 8(6):243-8. PubMed ID: 10582856
[TBL] [Abstract][Full Text] [Related]
6. Risk of a Down syndrome live birth in women 45 years of age and older.
Morris JK; De Vigan C; Mutton DE; Alberman E
Prenat Diagn; 2005 Apr; 25(4):275-8. PubMed ID: 15849789
[TBL] [Abstract][Full Text] [Related]
7. Health behaviour modelling for prenatal diagnosis in Australia: a geodemographic framework for health service utilisation and policy development.
Muggli EE; McCloskey D; Halliday JL
BMC Health Serv Res; 2006 Sep; 6():109. PubMed ID: 16945156
[TBL] [Abstract][Full Text] [Related]
8. Genetic counseling, prenatal screening and diagnosis of Down syndrome in the second trimester in women of advanced maternal age: a prospective study.
Qi QW; Jiang YL; Zhou XY; Liu JT; Yin J; Bian XM
Chin Med J (Engl); 2013; 126(11):2007-10. PubMed ID: 23769548
[TBL] [Abstract][Full Text] [Related]
9. Long-term trends for socio-economic differences in prenatal diagnosis of Down syndrome: diffusion of services or persistence of disparities?
Khoshnood B; De Vigan C; Blondel B; Vodovar V; Cadio E; Goffinet F
BJOG; 2008 Aug; 115(9):1087-95. PubMed ID: 18518869
[TBL] [Abstract][Full Text] [Related]
10. Nuchal translucency screening: how do women actually utilize the results?
Caughey AB; Musci TJ; Belluomini J; Main D; Otto C; Goldberg J
Prenat Diagn; 2007 Feb; 27(2):119-23. PubMed ID: 17152116
[TBL] [Abstract][Full Text] [Related]
11. Fifteen years of triple tests in The Netherlands; the life cycle of a screening test.
Wortelboer EJ; Koster MP; Stoutenbeek P; Loeber JG; Visser GH; Schielen PC
Prenat Diagn; 2008 Oct; 28(10):950-5. PubMed ID: 18821712
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of prenatal diagnosis intervention for Down's syndrome in China.
Chen Y; Qian X; Li J; Zhang J; Chu A; Schweitzer SO
Int J Technol Assess Health Care; 2007; 23(1):138-45. PubMed ID: 17234028
[TBL] [Abstract][Full Text] [Related]
13. Prenatal testing for Down syndrome in the Jewish and non-Jewish populations in Israel.
Davidov B; Goldman B; Akstein E; Barkai G; Legum C; Dar H; Romem Y; Amiel A; Cohen H; Bach G
Isr J Med Sci; 1994 Aug; 30(8):629-33. PubMed ID: 8045747
[TBL] [Abstract][Full Text] [Related]
14. Prevalence of Down syndrome in Glasgow, 1980-96--the growing impact of prenatal diagnosis on younger mothers.
Iliyasu Z; Gilmour WH; Stone DH
Health Bull (Edinb); 2002 Jan; 60(1):20-6. PubMed ID: 12664764
[TBL] [Abstract][Full Text] [Related]
15. A new policy for prenatal screening and diagnosis of Down syndrome for pregnant women with advanced maternal age in a public hospital.
Lo TK; Lai FK; Leung WC; Lau WL; Tang LC; Chin RK
J Matern Fetal Neonatal Med; 2010 Aug; 23(8):914-9. PubMed ID: 19883260
[TBL] [Abstract][Full Text] [Related]
16. Has prenatal screening influenced the prevalence of comorbidities associated with Down syndrome and subsequent survival rates?
Halliday J; Collins V; Riley M; Youssef D; Muggli E
Pediatrics; 2009 Jan; 123(1):256-61. PubMed ID: 19117890
[TBL] [Abstract][Full Text] [Related]
17. How important is consent in maternal serum screening for Down syndrome in France? Information and consent evaluation in maternal serum screening for Down syndrome: a French study.
Favre R; Duchange N; Vayssière C; Kohler M; Bouffard N; Hunsinger MC; Kohler A; Mager C; Neumann M; Vayssière C; Viville B; Hervé C; Moutel G
Prenat Diagn; 2007 Mar; 27(3):197-205. PubMed ID: 17238219
[TBL] [Abstract][Full Text] [Related]
18. Uptake of prenatal diagnostic testing and the effectiveness of prenatal screening for Down syndrome.
Jaques AM; Collins VR; Muggli EE; Amor DJ; Francis I; Sheffield LJ; Halliday JL
Prenat Diagn; 2010 Jun; 30(6):522-30. PubMed ID: 20509151
[TBL] [Abstract][Full Text] [Related]
19. Screening options for Down syndrome: how women choose in real clinical setting.
Lo TK; Lai FK; Leung WC; Lau WL; Ng LS; Wong WC; Tam SS; Yee YC; Choi H; Lam HS; Sham AS; Tang LC; Chin RK
Prenat Diagn; 2009 Sep; 29(9):852-6. PubMed ID: 19441088
[TBL] [Abstract][Full Text] [Related]
20. Maternal age-specific fetal loss rates in Down syndrome pregnancies.
Savva GM; Morris JK; Mutton DE; Alberman E
Prenat Diagn; 2006 Jun; 26(6):499-504. PubMed ID: 16634111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
